Schnyder corneal dystrophy is a rare genetic eye condition that causes cholesterol to build up in the clear front surface of the eye. People with Schnyder corneal dystrophy often notice glare, light sensitivity, and blurry vision that can slowly worsen over time. It usually begins in childhood or early adulthood and is lifelong, but not everyone will have the same experience. Vision loss varies and life expectancy is not affected. Treatment focuses on improving vision with glasses, contact lenses, or later procedures like laser polishing or corneal transplant, and managing light sensitivity with tinted lenses.
Overview
Schnyder corneal dystrophySymptoms
Schnyder corneal dystrophy features glare, light sensitivity, and blurred or hazy vision that often worsens slowly, especially with bright lights or at night. Doctors may see central corneal clouding or sparkling crystals. Many notice changes from childhood or early adulthood.
Outlook and prognosis
Most people with Schnyder corneal dystrophy keep good vision for years, though glare, halos, and gradual blurring can affect daily tasks like night driving. Eye doctors track changes and treat troublesome clouding or deposits when needed. Family members may benefit from genetic counseling and regular eye checks.
Causes and risk factors
Schnyder corneal dystrophy results from UBIAD1 gene variants, most often inherited in an autosomal dominant pattern. Main risk is having an affected parent; new mutations are uncommon. Cholesterol disorders and aging may influence severity, but they do not cause it.
Genetic influences
Genetics play a central role in Schnyder corneal dystrophy. Most cases result from inherited variations in the UBIAD1 gene, typically passed in an autosomal dominant pattern. Family history strongly guides risk, but expressivity and age at onset can vary.
Diagnosis
An ophthalmologist checks the cornea with a slit-lamp, looking for central crystals and a ring-like haze. Corneal imaging helps document the pattern and rule out other causes. Genetic testing of UBIAD1 can confirm the genetic diagnosis of Schnyder corneal dystrophy.
Treatment and drugs
Treatment for Schnyder corneal dystrophy focuses on clearer vision and comfort. Many do well with glasses, lubricating drops, or managing glare; when clouding or glare limits daily tasks, procedures like phototherapeutic keratectomy or corneal transplant can restore clarity. Genetic counseling may help families understand inheritance and plan care.
Symptoms
Bright light can feel harsh, and reading or driving with glare may take extra effort for many living with Schnyder corneal dystrophy. People often first notice glare or light sensitivity—early features of Schnyder corneal dystrophy—along with a gradual, mild blur that eyeglasses don’t fully fix. Over years, a central haze or tiny sparkling deposits can reduce contrast and make lights look starburst or haloed. Features vary from person to person and can change over time.
Bright rooms or sunlight can feel uncomfortable or painful. Sunglasses or dimming lights may become a daily need.
Headlights, streetlights, or screens can appear with halos, starbursts, or streaks. Night driving often feels especially challenging.
Vision may look slightly foggy or smeared, even with a recent glasses prescription. This happens because the cornea can become cloudy, not just because of focus issues.
Fine print and low-contrast details can be harder to make out. Colors may look a bit washed out, and dim settings can feel visually noisy.
How people usually first notice Schnyder corneal dystrophy?
Many first notice Schnyder corneal dystrophy when light starts to glare more than usual and vision looks hazy or blurred, especially in bright conditions. Eye doctors often spot the first signs of Schnyder corneal dystrophy during an exam by seeing tiny, needle-like cholesterol crystals or a cloudy ring in the central cornea, sometimes even in children or teens. Some families learn about it after a relative is diagnosed, prompting checks that reveal early corneal changes before symptoms are obvious.
Types of Schnyder corneal dystrophy
Schnyder corneal dystrophy is a rare, inherited eye condition that causes cholesterol to build up in the clear front window of the eye. Over time, this can cloud vision, create glare or halos, and make bright light uncomfortable during daily tasks like night driving or reading under overhead lights. Symptoms don’t always look the same for everyone. Clinicians often describe them in these categories: classic crystalline form, noncrystalline form, and an early childhood presentation; when people ask about types of Schnyder corneal dystrophy, they’re usually referring to these recognized clinical variants rather than different genes.
Classic crystalline form
Tiny, sparkling cholesterol crystals appear in the central cornea. People may notice glare, halos, and gradual blurring starting in childhood or early adulthood. The crystals can lessen with age while haze and light sensitivity persist.
Noncrystalline form
No visible crystals are seen, but a central corneal haze develops. Vision often blurs slowly, with bothersome glare—especially in bright light or at night. Doctors confirm the pattern with an eye exam and imaging.
Early-onset variant
Signs show up in childhood with early central haze and sometimes crystals. Kids may squint in sunlight or sit closer to screens due to glare and blur. Early symptoms of Schnyder corneal dystrophy can appear even before school age.
What genetics can tell you about symptoms
People with Schnyder corneal dystrophy often develop central corneal crystals, glare, and blurry vision because mutations in the UBIAD1 gene disrupt cholesterol handling in the cornea. Certain variants cause earlier, denser crystals and faster haze, while others lead to milder, later changes.
Causes and risk factors
The main cause is a change in a gene called UBIAD1 that upsets how the cornea handles cholesterol. Genetic causes of Schnyder corneal dystrophy are usually inherited from a parent, but a new gene change can appear for the first time. Genes set the stage, but environment and lifestyle often decide how the story unfolds. High cholesterol and other lipid problems can raise the chance of more crystal buildup and haze, and severity can vary even within one family. Getting older can make the changes more noticeable, and having close relatives with the condition is the strongest risk factor for developing Schnyder corneal dystrophy.
Environmental and biological risk factors
For Schnyder corneal dystrophy, the evidence for environmental risk factors is limited. When people ask about environmental risk factors for Schnyder corneal dystrophy, the honest answer is that none are clearly established. Researchers are still exploring how outside influences interact with our inner biology. At present, no common environmental or body-based factor has been shown to raise the chance that it occurs.
Advanced maternal age has not been shown to increase the chance of Schnyder corneal dystrophy. No consistent association has been found.
Advanced paternal age does not appear to raise risk. Evidence to date has not demonstrated a clear connection.
Health conditions during pregnancy have no proven link to causing this dystrophy. Current evidence does not show they change the likelihood.
No specific medication exposure in pregnancy has been tied to higher risk of this dystrophy. Talk with your doctor about both your biological and environmental risks.
Genetic risk factors
Schnyder corneal dystrophy often runs in families due to changes in a single gene that affect how cholesterol is handled in the clear front of the eye. Some risk factors are inherited through our genes. The genetic causes of Schnyder corneal dystrophy center on variants in the UBIAD1 gene and a dominant pattern of inheritance, which means the condition can pass from one generation to the next. Understanding these patterns can guide genetic testing and help families discuss who else may be at risk.
UBIAD1 gene variants: Changes in the UBIAD1 gene are the main genetic cause of Schnyder corneal dystrophy. They disrupt how the cornea handles cholesterol and other lipids. Most families with the condition have a detectable variant in this gene.
Autosomal dominant pattern: One altered copy of UBIAD1 is enough to cause the disorder. Each child of an affected parent has a 50% (1 in 2) chance to inherit the variant. This risk is the same for males and females.
Variable expressivity: People with the same UBIAD1 variant can show different severity and timing of eye changes. One relative may have obvious corneal crystals while another has mainly haze. Many carriers develop clearer signs by adulthood.
De novo changes: Sometimes a new UBIAD1 variant appears in someone with no family history. In these cases, both parents usually test negative for the variant. The affected individual can still pass the variant to future children.
Age-related penetrance: Genetic effects often become more apparent with age, so early eye findings can be subtle. A child who carries the variant may show clearer corneal changes later in life. This timing does not change the inherited risk.
Founder effects: In some regions or extended families, the same UBIAD1 change is shared from a common ancestor. This can cluster Schnyder corneal dystrophy within certain communities. It does not imply a higher risk outside those lineages.
Genetic testing: Sequencing UBIAD1 can confirm Schnyder corneal dystrophy and identify the familial variant. Testing at-risk relatives can clarify who carries the change and who does not. Results can guide who needs ongoing cornea checks.
Family history clues: Multiple generations with similar corneal findings raise the likelihood of a UBIAD1 variant. Mapping who is affected helps target testing efficiently. This can also inform discussions about genetic risk in the family.
Lifestyle risk factors
Schnyder corneal dystrophy is an inherited condition; lifestyle habits do not cause it. However, daily choices can influence lipid levels and ocular surface comfort, which may affect how symptoms progress or how often interventions are needed. Understanding how lifestyle affects Schnyder corneal dystrophy can help you support vision and reduce bothersome glare.
Choosing fewer saturated and trans fats and more soluble fiber can lower LDL cholesterol and triglycerides. In Schnyder corneal dystrophy, better lipid profiles may slow stromal cholesterol buildup and reduce haze over time.
Consistent aerobic and resistance activity improves HDL, lowers triglycerides, and enhances insulin sensitivity. In this condition, improved lipid metabolism may limit corneal lipid deposition and help stabilize visual clarity.
Maintaining a healthy weight reduces dyslipidemia and metabolic syndrome. For people with Schnyder corneal dystrophy, this may lessen the rate of corneal cholesterol accumulation and slow glare and halos.
Smoking increases oxidative stress and impairs corneal healing. Quitting may reduce symptom flare-ups and support clearer outcomes after procedures such as PTK or keratoplasty in this condition.
Risk prevention
You can’t fully prevent Schnyder corneal dystrophy because it’s inherited, but you can lower the chance of vision problems by protecting your eyes, managing cholesterol, and staying on top of routine care. Prevention is about lowering risk, not eliminating it completely. Regular eye checks can spot early symptoms of Schnyder corneal dystrophy—like glare, halos, or cloudy central spots—before they make reading or night driving hard.
Schedule comprehensive eye exams every 6–12 months to track corneal changes. Early findings guide timely steps that can protect day-to-day vision.
Work with your doctor on cholesterol targets, which may include food changes, exercise, or medication. Better lipid control can help limit the buildup linked to Schnyder corneal dystrophy.
Wear UV-blocking sunglasses and a brimmed hat outdoors. Reducing glare can ease light sensitivity and improve comfort.
Use preservative-free artificial tears and practice gentle eyelid hygiene. A well-lubricated surface reduces irritation and the urge to rub your eyes.
Transmission
Schnyder corneal dystrophy is not infectious and cannot be caught from someone else. It results from a change in a single gene and most often follows an autosomal dominant pattern—if a parent has Schnyder corneal dystrophy, each child has a 50% chance of inheriting it. Less commonly, the condition can arise from a new gene change, with no previous family history. Genetic counseling can explain the genetic transmission of Schnyder corneal dystrophy, help assess family risk, and discuss testing options. Everyday contact, shared towels, or eye exams do not spread it.
When to test your genes
Consider genetic testing if you have Schnyder corneal dystrophy, unexplained early cholesterol deposits in the cornea, or a close relative with the condition. Testing can confirm the diagnosis, guide eye-care plans, and identify at‑risk family members for earlier monitoring. A genetics professional can help choose the right test and interpret results.
Diagnosis
Diagnosis usually begins with an eye exam that looks closely at the clear front surface of the eye and how well you see in different lighting. The genetic diagnosis of Schnyder corneal dystrophy is usually confirmed after doctors see a typical pattern of tiny crystals or haze in the central cornea. Getting a diagnosis is often a turning point toward answers and support. Genetic testing can then verify the underlying change and help guide family screening.
An eye doctor examines the cornea under magnification to look for central clouding, tiny sparkling crystals, or a ring of cholesterol at the edge. These clinical features are the main clues to Schnyder corneal dystrophy.
A detailed family and health history can help identify relatives with similar eye findings or early vision issues. Because Schnyder corneal dystrophy often runs in families, patterns across generations support the diagnosis.
Standard checks of visual acuity and contrast, sometimes with glare testing, show how much the corneal changes affect daily seeing. Results also help track progression over time.
Anterior segment OCT creates cross‑section images that show where deposits and haze sit in the cornea. These imaging findings can support a diagnosis of Schnyder corneal dystrophy and document baseline severity.
Stages of Schnyder corneal dystrophy
Vision changes in this condition tend to build over years, and eye doctors describe three broad stages. Different tests may be suggested to help map where you are in the course and guide care. Schnyder corneal dystrophy often starts in childhood or early adulthood, but the impact on day-to-day vision may not be felt until later.
Stage 1
Early changes: Fine cloudiness appears in the center of the cornea, sometimes with tiny sparkly crystals. Early symptoms of Schnyder corneal dystrophy can be subtle, like mild glare or trouble with bright lights. An eye exam with a slit lamp can confirm these early findings.
Stage 2
Arcus forms: A cholesterol arc near the corneal edge develops and the central haze spreads outward. People with Schnyder corneal dystrophy may notice more glare and halos at night, while reading vision can still be fairly clear. Doctors may document this stage with corneal photos and regular vision checks to track change.
Stage 3
Diffuse haze: The cloudiness involves much of the cornea and crystals may be harder to see as the haze thickens. Blurred vision becomes more noticeable and may affect driving or reading, sometimes prompting treatment discussions. A corneal specialist may talk through options such as surface laser polishing or a partial-thickness transplant if needed.
Outlook and prognosis
Looking ahead can feel daunting, but most people with Schnyder corneal dystrophy can expect a long lifespan and a stable day-to-day routine. Vision changes usually unfold slowly over years. Early symptoms of Schnyder corneal dystrophy often include glare and trouble seeing in bright light or at night; reading fine print or driving at dusk may become harder before daytime vision noticeably blurs. Over time, the cornea can become cloudier as cholesterol deposits build, but many living with Schnyder corneal dystrophy maintain functional vision for decades with good eye care.
This brings us to what doctors call the outlook, or prognosis. The condition primarily affects the clear front surface of the eye and does not typically harm the rest of the body, so mortality is not increased because of Schnyder corneal dystrophy itself. Visual prognosis varies: some people notice mild haze and glare only, while others develop more significant clouding that affects daily tasks. If vision does decline, treatments such as specialized contact lenses, laser procedures, or corneal transplantation can improve clarity; results are often good, though changes can gradually return over time.
Genetic testing can sometimes provide more insight into prognosis. Because the condition can run in families, close relatives may benefit from eye exams to spot early changes and plan follow-up. Knowing what to expect can ease some of the worry. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Schnyder corneal dystrophy tends to change slowly over many years, as tiny fat and cholesterol deposits build up in the clear front window of the eye. Early symptoms of Schnyder corneal dystrophy often include glare and trouble with bright lights, with sharper vision gradually declining later on. Long-term effects vary widely, with some people staying fairly stable for decades while others notice slow, steady change. When vision gets cloudy enough to interfere with daily life, corneal surgery can restore clarity for many.
Central vision often softens over decades as corneal clouding increases. Peripheral vision usually stays intact. Changes tend to be slow rather than sudden.
Bright light may feel harsh, and halos around lights are common. Sunlight and night headlights can be especially bothersome. This often appears earlier than major vision loss.
Reduced contrast and increased glare can make night roads and oncoming lights hard to manage. People may slow down driving at night or avoid poorly lit areas. This can progress gradually.
Tiny, shimmering crystals may be seen in the cornea, especially in younger adults. Over time these crystals can become less obvious while the background haze increases. Not everyone with the condition shows visible crystals.
How is it to live with Schnyder corneal dystrophy?
Living with Schnyder corneal dystrophy often means noticing glare and halos around lights, trouble with night driving, and gradually blurrier vision as tiny cholesterol crystals and haze build up in the cornea. Daily life can involve planning around lighting, using sunglasses with good UV and polarization, and seeing an eye specialist regularly; many do well for years with these adjustments, while some eventually need procedures like laser polishing of the cornea or a corneal transplant to improve clarity. Family members may share driving, help with bright-light environments, and consider their own eye exams, since this condition can run in families. With the right follow-up and adaptive tools, many keep working, reading, and staying active, even if they move a bit more carefully through dim rooms and nighttime streets.
Treatment and drugs
Schnyder corneal dystrophy is managed by easing glare and improving vision early on, then treating clouding of the cornea if it progresses. Early steps often include sunglasses or tinted lenses for light sensitivity, lubricating eye drops for comfort, and corrective glasses or contact lenses; some people benefit from specially coated lenses that cut glare. If vision worsens from corneal haze or central deposits, doctors may remove surface deposits with a minor procedure (called superficial keratectomy) or reshape the front layer with laser (phototherapeutic keratectomy) to clear the line of sight, though changes can slowly return over time. For advanced scarring or severe clouding, a corneal transplant—often a partial-thickness graft that replaces the front layers—can restore clearer vision, with regular follow-up to watch for rejection and recurrence. Your doctor can help weigh the pros and cons of each option.
Non-drug treatment
Schnyder corneal dystrophy can make day-to-day vision feel hazy, with glare and light sensitivity that complicate driving, screen time, and time outdoors. Care focuses on comfort and clearer sight, and the plan usually changes as the cornea changes over time. Non-drug treatments often lay the foundation for stable vision and safer daily activities. When vision drops despite these steps, procedures on the cornea may be considered.
Routine visits help spot early symptoms of Schnyder corneal dystrophy and track changes in the cornea. Your eye doctor can time procedures and lens options for the best window of benefit.
Wraparound sunglasses, a brimmed hat, and anti-glare lenses can ease light sensitivity. This won’t slow the condition but often makes driving and outdoor time more comfortable.
Rigid lenses can create a smoother optical surface over corneal deposits in Schnyder corneal dystrophy. This may sharpen focus and cut down on glare, but they need careful fitting and follow-up.
These larger lenses vault over the cornea and hold a layer of fluid against it. They can improve clarity and comfort for many, especially when light sensitivity is prominent.
Your genes may have an impact on how drugs work for you
Some medicines for Schnyder corneal dystrophy—and for related issues like lipid control—can work differently based on genes that affect drug processing and cholesterol pathways. Genetic differences may change effectiveness or side‑effect risk, so personalized dosing or alternatives might be recommended.
Pharmacological treatments
Day-to-day, medicines for Schnyder corneal dystrophy aim to ease eye comfort and manage cholesterol; they do not remove the corneal crystals themselves. Early symptoms of Schnyder corneal dystrophy can include glare, light sensitivity, and fluctuating blur, which lubricating drops may help. Some people also need cholesterol-lowering drugs for overall health and to limit further lipid buildup. Not everyone responds to the same medication in the same way.
Artificial tears such as carboxymethylcellulose or hypromellose can ease dryness, burning, and light sensitivity. Preservative-free options are best if you use them often. They won’t clear corneal deposits in Schnyder corneal dystrophy but can steady day-to-day comfort.
Petrolatum–mineral oil eye ointments before bed reduce morning irritation and blur. They help protect the corneal surface overnight. Expect brief blur right after applying.
Atorvastatin or rosuvastatin lower LDL cholesterol when it’s high, which can occur in families with Schnyder corneal dystrophy. These drugs support heart health and may help limit further lipid accumulation, but they do not remove existing corneal crystals. Blood tests and occasional liver enzyme checks are routine.
Ezetimibe lowers LDL by blocking cholesterol absorption in the gut and is often added if a statin alone isn’t enough. It has a low side‑effect burden for many. It doesn’t reduce corneal haze from Schnyder corneal dystrophy.
Genetic influences
In most families, Schnyder corneal dystrophy is caused by a single inherited change in a gene called UBIAD1. One altered copy is enough to cause the condition, so each child of an affected parent has a 1 in 2 (50%) chance of inheriting the same gene change. UBIAD1 helps cells handle fats and cholesterol in the clear front surface of the eye; when it doesn’t work as it should, tiny deposits can build up over time. Even within the same family, the age when signs appear and whether shiny crystals are seen can differ, so early symptoms of Schnyder corneal dystrophy vary from person to person. Genetic testing may look for changes in UBIAD1. DNA testing can sometimes identify these changes. Because blood cholesterol can be normal or raised and doesn’t predict the eye findings, relatives are often flagged by family history and an eye exam rather than lab values.
Is Schnyder corneal dystrophy genetic?
Genetics play a central role in Schnyder corneal dystrophy. Most cases result from inherited variations in the UBIAD1 gene, typically passed in an autosomal dominant pattern. Family history strongly guides risk, but expressivity and age at onset can vary.
Pharmacogenetics—how genetics influence drug effects
Because Schnyder corneal dystrophy stems from inherited gene changes that alter how cholesterol is handled in the cornea, care usually focuses on the eye itself—comfort drops, glare control, laser smoothing of the surface, or a corneal transplant if vision is significantly reduced. There isn’t a medicine proven to dissolve the corneal crystals, and drug response in Schnyder corneal dystrophy hasn’t been tied to a specific gene test. If you also need cholesterol‑lowering therapy for your overall health, common gene differences that affect how the body handles certain statins may influence side effects and the dose that’s right for you. Genetics is only one factor; your age, other medicines, and overall health also shape how you respond. For eye procedures used in Schnyder corneal dystrophy, anesthesia and pain medicines are typically chosen based on your medical history rather than any SCD‑specific genetic result. At this time, pharmacogenetic testing isn’t routinely recommended just for Schnyder corneal dystrophy, but it can help guide medicines with established gene–drug guidance when those are part of your treatment plan.
Interactions with other conditions
People with Schnyder corneal dystrophy often live with common health issues seen in the general population, and cholesterol levels are a frequent question. Some have high cholesterol or other lipid changes, while many have perfectly normal blood tests; either way, the eye findings of Schnyder corneal dystrophy are the main driver of vision symptoms. Doctors call it a “comorbidity” when two conditions occur together, and when high cholesterol is present, treating it helps heart and stroke risk, even though it usually doesn’t clear the corneal crystals or haze.
If diabetes, age‑related macular degeneration, or significant cataract is also present, the corneal clouding from Schnyder corneal dystrophy can make vision testing, retinal imaging, and even cataract measurements a bit harder, and glare may feel worse than expected from cataracts alone. In practical terms, early symptoms of Schnyder corneal dystrophy—such as glare and halos—can amplify the day‑to‑day impact of other eye diseases that already reduce contrast or clarity. Medication interactions are not a major concern, and drugs that lower cholesterol generally do not harm the cornea; they just may not change the deposits. Let your eye specialist and primary care team share information, so plans for lipid management, diabetes care, and any eye procedures are coordinated and tailored to you.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described families where several relatives developed cloudy, glitter-like changes in the front window of the eye and gradually blurred vision. Community stories often described the condition appearing in midlife, then showing up again in the next generation. Early doctors noted rings or patches in the clear cornea that looked like tiny crystals and sometimes a haze that spread over time, but they did not know why it happened or how it ran in families.
First described in the medical literature as a corneal dystrophy with “cholesterol crystals,” Schnyder corneal dystrophy drew attention because the cornea itself—normally free of blood vessels—seemed to collect cholesterol and fats. Initially understood only through symptoms, later observations connected the sparkly deposits to progressive vision changes and light sensitivity. Over time, descriptions became more precise: some people had obvious crystal-like spots, while others showed more of a milky clouding without visible crystals. This helped explain why the condition was sometimes missed in its early stages.
In recent decades, knowledge has built on a long tradition of observation. Careful family histories showed a clear inheritance pattern, where having one affected parent often meant a higher chance of having Schnyder corneal dystrophy. Not every early description was complete, yet together they built the foundation of today’s knowledge. As medical science evolved, improved imaging of the cornea allowed clinicians to see the depth and spread of deposits more clearly, track changes over time, and distinguish this dystrophy from other causes of corneal haze.
Advances in genetics confirmed what families had long noticed. Researchers identified changes in a gene involved in handling cholesterol and other lipids inside cells, helping explain why deposits build up in the cornea. This finding also clarified why some people with Schnyder corneal dystrophy have features outside the eye, such as higher cholesterol levels, while others do not. The genetic discoveries did not change the day-to-day experience of glare or gradually blurrier vision, but they offered clearer diagnosis, family counseling, and more targeted follow-up.
Today, the history of Schnyder corneal dystrophy traces a path from careful bedside observation to corneal imaging and genetic testing. Knowing the condition’s history helps explain its variability—why one family member may show bright crystalline flecks in their 20s while another develops mostly haze decades later. It also shows how steady, detailed clinical notes, combined with modern tools, turned scattered reports into a well-defined condition with a name, a cause, and a clearer outlook for people living with it.